Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...

In a report released on February 1, Casey Woodring from J.P. Morgan maintained a Hold rating on Charles River Labs (CRL – Research Report), ...

Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

Fifth Third Bancorp cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, indicating future capital deployment.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Members of Congress and animal rights advocates believe the Department of Government Efficiency could end animal testing ...

Fintel reports that on January 17, 2025, UBS downgraded their outlook for Charles River Laboratories International (NYSE:CRL) from Buy to Neutral. Analyst Price Forecast Suggests 32.82% Upside As of ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.